Drug intelligence / Profile preview

Sympathyl

Development stage: Unknown
Lead developer: Laboratoire Innotech
Modality: Small Molecules
Administration: Oral

Overview

Sympathyl is an oral combination product containing magnesium oxide, hawthorn (*Crataegus oxyacantha*) extract, and California poppy (*Eschscholtzia californica*) extract. Developed and marketed by Laboratoire Innotech International, it is used for the symptomatic treatment of mild-to-moderate anxiety, nervous tension, and sleep disturbances. It is also indicated for functional symptoms of increased cardiac excitability in adults with a healthy heart. The mechanism of action is multifaceted: magnesium supports electrolyte balance and neuromuscular function; hawthorn is traditionally used for cardiovascular support and reducing cardiac excitability; and California poppy provides mild anxiolytic and sedative effects.

Brand names: Sympathyl
Other names: Magnesium oxide / Hawthorn / Eschscholtzia

Beyond the preview

Go deeper on Sympathyl.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sympathyl.

Explore the full profile